Mizuho analyst Graig Suvannavejh raised the firm’s price target on Insmed to $36 from $35 and keeps a Buy rating on the shares following the Q1 report. The firm sees potential for a significant re-rating of the shares on positive data.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
